[Lung transplantation].
Lung transplantation is now an effective therapy for patients of less than 60 years-old with chronic end-stage lung diseases which life expectancy is less than 12 to18 months in spite of maximal medical therapy. The various surgical procedures (single or bilateral lung or heart-lung transplantation) offer an adapted solution to all the candidates whatever the cause of the respiratory disease. The early postoperative mortality is less than 10% and the survival rates regularly improve and reach 65 to 7% at 3 years and more than 50% at 5 years for experienced programmes. Primary graft dysfunction, infections and airways complications are the main causes of early morbidity. Bronchiolitis obliterans is the main limiting factor of the long-term survival. Malignancies and drug toxicity, such as renal or vascular complications, occur also at that time.
Stern
Marc
M
Groupe de transplantation pulmonaire, service de pneumologie, hôpital Foch, 92151 Suresnes. m.stern@hopital-foch.org
Bonnette
Pierre
P
D000328:Adult; D000367:Age Factors; D001989:Bronchiolitis Obliterans / Q000209:etiology; D005602:France; D006084:Graft Rejection / Q000209:etiology; D016041:Heart-Lung Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008171:Lung Diseases / Q000601:surgery; D008175:Lung Neoplasms / Q000209:etiology; D016040:Lung Transplantation / Q000502:physiology; D008875:Middle Aged; D018579:Patient Selection; D011183:Postoperative Complications; D013530:Surgical Wound Infection / Q000209:etiology; D015996:Survival Rate
D007166:Immunosuppressive Agents